Phase 1b/2a Study of Gemcitabine and Nab-paclitaxel in Combination with VS-6766 and Defactinib in Patients with Previously Untreated Metastatic Adenocarcinoma of the Pancreas

Brief description of study

This study is about testing a combination of drugs (gemcitabine, nab-paclitaxel, VS-6766, and defactinib) to treat a type of cancer called pancreatic ductal adenocarcinoma (PDAC). The study will be done in two parts, part A and Part B. In Part A, doctors will try to find the best dose of the combination of the drugs that can be given to a patient with out causing too many side effects (or referred to as dose-limiting toxicities). They will start with a low dose and gradually increase it as long as no side effects appear. They will also monitor patients closely for any side effects. In Part B, they will give more patients the best dosage of the combination of drugs they found in Part A to see if it works well to treat PDAC. The study will closely monitor for any side effects that patients may experience while taking the drugs.


Clinical Study Identifier: s22-01504
Principal Investigator: Kristen Spencer.
Other Investigators: Daniel J Becker, Carol M Lee, Jonathan B Kahn, Keriann M Scavone, Nina Beri, Jennifer Chuy, Paul E. Oberstein, Rafael Winograd, Shun Yu.


If you are registered as a volunteer, please log in to contact the study team/express interest in this study.

Contact the research team to learn more about this study.

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.